ArticleJournal of inflammation research2025
Yuyang Decoction Regulates Macrophage Polarization and Repairs the Intestinal Mucosal Barrier via the TLRs/Tollip Signaling Pathway.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by relapsing inflammation and impaired intestinal epithelial barrier. Current treatments have limitations, prompting interest in traditional Chinese medicine as potential alternatives. Yuyang Decoction (YYD) is a traditional formula with observed gastrointestinal protective effects, but its mechanisms remain unclear. Objective: To evaluate the therapeutic effects and underlying mechanisms of YYD on intestinal mucosal barrier repair in a UC mouse model. Methods: UC was induced in male C57/BL6 mice using 3% dextran sulfate sodium (DSS). Mice were randomly assigned to six groups: control, DSS model, low/medium/high-dose YYD, and mesalazine (positive control). Disease activity index (DAI), colon length, histopathology, cytokine levels, and tight junction protein expression were assessed. Tollip and IKK-β levels were detected by Western blot and immunofluorescence. Active components in YYD-containing serum were identified by UPLC-Q-Tof-MS/MS. In vitro, Tollip knockdown in THP-1 macrophages examined YYD's effect on macrophage polarization and Caco-2 cell barrier integrity. Results: YYD significantly reduced DAI scores, reversed colon shortening, and alleviated histological damage. Expression of tight junction proteins (occludin, claudins, ZO-1) and Tollip was upregulated. YYD-containing serum suppressed LPS-induced M1 macrophage polarization and protected epithelial tight junctions in vitro. These effects were diminished upon Tollip silencing. Conclusion: YYD alleviates DSS-induced colitis by enhancing intestinal barrier repair and modulating immune responses. Its therapeutic effect may involve activation of the Tollip signaling pathway, which inhibits pro-inflammatory M1-like macrophage differentiation and reduces epithelial damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.